Gene: PLCXD2
Official Full Name: phosphatidylinositol specific phospholipase C X domain containing 2provided by HGNC
Gene Summary: Predicted to enable phosphoric diester hydrolase activity. Predicted to be involved in lipid catabolic process and signal transduction. Predicted to be located in nucleus. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO09684 | PLCXD2 Knockout cell line (HeLa) | Human | PLCXD2 | 1:3~1:6 | Negative | Online Inquiry |
KO09685 | PLCXD2 Knockout cell line (HCT 116) | Human | PLCXD2 | 1:2~1:4 | Negative | Online Inquiry |
KO09686 | PLCXD2 Knockout cell line (HEK293) | Human | PLCXD2 | 1:3~1:6 | Negative | Online Inquiry |
KO09687 | PLCXD2 Knockout cell line (A549) | Human | PLCXD2 | 1:3~1:4 | Negative | Online Inquiry |
PLCXD2 Gene Knockout Cell Lines are invaluable research tools engineered to lack the phospholipase C delta 2 (PLCXD2) gene, a critical component in various signal transduction pathways. These cell lines enable researchers to investigate the role of PLCXD2 in cellular processes such as proliferation, differentiation, and apoptosis by providing a precise knockout model. This model is particularly beneficial for studying the gene's involvement in pathophysiological conditions, including cancer, neurodegeneration, and cardiovascular diseases, where PLCXD2 is suspected to play pivotal roles.
The key mechanism underlying these knockout cell lines lies in the CRISPR-Cas9 genome-editing technology, which has been deployed to induce targeted mutations in the PLCXD2 gene. This precise alteration leads to the complete absence of functional PLCXD2 protein, allowing scientists to explore the downstream effects of its loss on cellular functions. By comparing these knockout cells to their wild-type counterparts, researchers can garner insights into the biological consequences of PLCXD2 deletion, elucidating its signaling pathways and biological interactions.
The scientific importance of these cell lines extends to both academic and clinical research. They provide a robust platform for drug discovery, enabling high-throughput screening of potential therapeutics aimed at modulating PLCXD2 activity. Furthermore, the insights gained from these studies can inform the development of targeted therapies that may enhance patient outcomes in conditions where PLCXD2 is implicated.
Compared to alternative gene knockout models, our PLCXD2 Gene Knockout Cell Lines offer several distinct advantages. The availability of fully characterized lines ensures reproducibility and reliability in experimental outcomes, while our expert validation process guarantees the effective disruption of PLCXD2 expression. Additionally, these cell lines are compatible with various culture conditions and can be readily adapted for diverse experimental needs.
Researchers and clinicians can greatly benefit from PLCXD2 Gene Knockout Cell Lines as they provide an essential platform for understanding the intricate biology of PLCXD2 while facilitating the development of targeted intervention strategies. Our commitment to scientific excellence is reflected in the quality and reliability of our products, supported by our extensive expertise in cellular technologies and genetic engineering. With PLCXD2 Gene Knockout Cell Lines, you can advance your research and clinical applications with confidence, knowing you have a superior product at your disposal.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.